期刊文献+

它莫西芬对绒毛膜癌细胞株JAR补体调节蛋白表达的影响 被引量:1

Tamoxifen Modulates the Expression of Complement Inhibitory Proteins on Choriocarcinoma Cell Line JAR
原文传递
导出
摘要 为探索抗肿瘤药物Tamoxifen对绒毛膜癌细胞株JAR表面补体调节蛋白表达的影响 ,实验以绒毛膜癌细胞株JAR为研究对象 ,用流式细胞术和RT PCR分别检测Tamoxifen作用前后JAR细胞补体调节蛋白在蛋白质和mRNA水平的表达。结果显示 :在 10 6MTamoxifen作用 3d后 ,JAR细胞补体调节蛋白DAF和CD5 9的蛋白质表达水平明显降低 ,而MCP无明显改变 ;在 10 6MTamoxifen作用 2 4h后 ,JAR细胞DAF和CD5 9mRNA表达水平分别降低 88%和 6 0 %。提示Tamoxifen可能通过降低DAF和CD5 9的表达 。 This study was designed to elucidate the role of anti tumor drug Tamoxifen in the expression of complement inhibitory proteins MCP,DAF and CD59 on choriocarcinoma cell line JAR JAR cells were cultured in vitro,stimulated with Tamoxifen for different time,and the expression of complement inhibitory proteins in protein and mRNA level were analyzed by flow cytometry and RT PCR Treated with Tamoxifen,the expression of complement inhibitory proteins on JAR in protein and mRNA level were significantly decreased Our study demonstrated that down regulation of the expression of complement inhibitory proteins may be a new mechanism of Tamoxifen to suppress tumor growth by enhancing the sensitivity of malignant cells to the host complement attack
出处 《上海免疫学杂志》 CSCD 北大核心 2003年第1期20-23,共4页 Shanghai Journal of Immunology
关键词 TAMOXIFEN 补体调节蛋白 绒毛膜癌 JAR Tamoxifen complement inhibitory proteins choriocarcinoma JAR
  • 相关文献

参考文献13

  • 1Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy,and side effects[J]. J Clin Oncol, 1989,7:803. 被引量:1
  • 2Palomba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women[J]. Fertil Steril,2001,76:38. 被引量:1
  • 3Sadan O,Ginath S,Sofer D, et al. The role of Tamoxifen in the treatment of symptomatic uterine leiomyoma-a pilot study[J]. Eur J Obstet Gynecol Reprod Biol,2001,96:183. 被引量:1
  • 4Juhl H, Helmig F, Baltzer K, et al. Frequent expression of complement resistant factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A [J] . J Surg Oncol, 1997,64:222. 被引量:1
  • 5Mandlekar S,Yu R,Tan TH,et al. Activation of Caspase 3 and c-jun NH2-terminal kinase-1 signaling pathways in Tamoxifen-induced apoptosis of human breast cancer cells[J]. Cancer Res,2001,60:5995. 被引量:1
  • 6Buckley DJ, Chapman MA, Durrant LG, et al. Increased expression of 79lt-Gp72 predicts a poor prognosis in colorectal cancer[J]. Gastroenterology, 1996,110: A497. 被引量:1
  • 7Coral S, Fonsatti E, Sigalotti L, et al. Overexpression of protection (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement[J]. J Cell Physiol, 2000, 185 : 317. 被引量:1
  • 8Jurianz K, Ziegler S, Donin N, et al. K.562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement[J]. Int J Cancer,2001,93:848. 被引量:1
  • 9Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells:basal and induced mechanisms[J]. Mol Immunol, 1999,36: 929. 被引量:1
  • 10Denton GWL, Durrant LG, Hardcastle JD, et al. Clinical outcome of colorectal cancer patients treated with human monoclonal antiidiotypic antibody[J]. Int J Cancer, 1994,57 : 10. 被引量:1

同被引文献25

  • 1王芹,张玲,张维东,魏丽,贾青.胃癌组织衰变加速因子表达及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(9):683-686. 被引量:8
  • 2Dunn GP,Old LJ,Schreiber RD. The immunobiology of cancer immunosurveillanee and immunoediting[J].Immunity,2004,(02):137-148.doi:10.1016/j.immuni.2004.07.017. 被引量:1
  • 3Fishelson Z,Donin N,Zell S. Obstacles to cancer immunotherapy:expression of membrane complement regulatory proteins (mCRPs) in tumors[J].Molecular Immunology,2003,(2/4):109-123. 被引量:1
  • 4De Nardo C,Fonsatti E,Sigalotti L. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells[J].Journal of Cellular Physiology,2002,(02):200-206. 被引量:1
  • 5Lukacik P,Roversi P,White J. Complement regulation at the molecular level:the structure of decay-accelerating factor[J].Proceedings of the National Academy of Sciences(USA),2004,(05):1279-1284. 被引量:1
  • 6Ravindranath NM,Shuler C. Cell-surface density of complement restriction factors (CD46,CD55,and CD59):oral squamous cell carcinoma versus other solid rumors[J].Oral Stag Oral Med Oral Pathol Oral Radiol Ended,2007,(02):231-239. 被引量:1
  • 7Tae-Hwa Baek,Joo-Heon Kim,Mee-Ja Park. The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients[J].Korean Journal of Plant Pathology,2011,(05):445-454. 被引量:1
  • 8Mustafa T,Klonisch T,Hombach-Klonisch S. Expression of CD97 and CD55 in human medullary thyroid carcinomas[J].International Journal of Oncology,2004,(02):285-294. 被引量:1
  • 9Loberg RD,Day LL,Dunn R. Inhibition of decayaccelerating factor (CD55) attenuates prostate cancer growth and survival in vivo[J].Neoplasia,2006,(01):69-78. 被引量:1
  • 10Bj(o)rge L,Stoiber H,Dierieh MP. Minimal residual disease in ovarian cancer as a targe:for complement-mediated mAb immunotherapy[J].Scandinavian Journal of Immunology,2006,(05):355-364. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部